Mineralys Therapeutics, Inc. (MLYS)
NASDAQ (NGS) NASDAQ (NGS) Primary 
Bronstein, Gewirtz & Grossman, LLC Encourages Mineralys Therapeutics, Inc.(MLYS) Investors to Inquire about Securities Investigation
NEW YORK CITY, NY / ACCESSWIRE / September 11, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Mineralys Therapeutics, Inc. ("Mineralys" or "the Company") (NASDAQ:MLYS). Investors who purchased Mineralys securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/MLYS.
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Mineralys Therapeutics, Inc.(MLYS) And Encourages Investors to Reach Out
NEW YORK CITY, NY / ACCESSWIRE / September 10, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Mineralys Therapeutics, Inc. ("Mineralys" or "the Company") (NASDAQ:MLYS). Investors who purchased Mineralys securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/MLYS.
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Mineralys Therapeutics, Inc.(MLYS) And Encourages Stockholders to Reach Out
NEW YORK CITY, NY / ACCESSWIRE / September 9, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Mineralys Therapeutics, Inc. ("Mineralys" or "the Company") (NASDAQ:MLYS). Investors who purchased Mineralys securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/MLYS.
Mineralys Therapeutics Inc May Have Violated Securities Laws And Shareholders Are Invited To Help The Schall Law Firm's Inquiry
LOS ANGELES, CA / ACCESSWIRE / September 9, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Mineralys Therapeutics, Inc. ("Mineralys" or "the Company") (NASDAQ:MLYS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mineralys Therapeutics, Inc. - MLYS
NEW YORK, NY / ACCESSWIRE / September 7, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Mineralys Therapeutics, Inc. ("Mineralys" or the "Company") (NASDAQ:MLYS). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mineralys Therapeutics, Inc. - MLYS
NEW YORK, NY / ACCESSWIRE / September 5, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Mineralys Therapeutics, Inc. ("Mineralys" or the "Company") (NASDAQ:MLYS). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mineralys Therapeutics, Inc. - MLYS
NEW YORK, NY / ACCESSWIRE / September 1, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Mineralys Therapeutics, Inc. ("Mineralys" or the "Company") (NASDAQ:MLYS). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mineralys Therapeutics, Inc. - MLYS
NEW YORK, NY / ACCESSWIRE / August 30, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Mineralys Therapeutics, Inc. ("Mineralys" or the "Company") (NASDAQ:MLYS). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mineralys Therapeutics, Inc. - MLYS
NEW YORK, NY / ACCESSWIRE / August 28, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Mineralys Therapeutics, Inc. ("Mineralys" or the "Company") (NASDAQ:MLYS). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mineralys Therapeutics, Inc. - MLYS
NEW YORK, NY / ACCESSWIRE / August 24, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Mineralys Therapeutics, Inc. ("Mineralys" or the "Company") (NASDAQ:MLYS). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mineralys Therapeutics, Inc. - MLYS
NEW YORK, NY / ACCESSWIRE / August 22, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Mineralys Therapeutics, Inc. ("Mineralys" or the "Company") (NASDAQ:MLYS). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mineralys Therapeutics, Inc. - MLYS
NEW YORK, NY / ACCESSWIRE / August 19, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Mineralys Therapeutics, Inc. ("Mineralys" or the "Company") (NASDAQ:MLYS). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
